Citius shares surge 10.23% intraday as LYMPHIR exhibition at ASH 2025 and Q4 2025 launch timeline boost investor optimism.

Citius Oncology (CTOR) surged 10.23% intraday after announcing its participation in the 67th American Society of Hematology (ASH) Annual Meeting, where it will showcase LYMPHIR, its FDA-approved IL-2 receptor-directed fusion protein for cutaneous T-cell lymphoma (CTCL). The news highlights LYMPHIR’s commercialization progress, with a launch slated for Q4 2025, and positions the drug as a targeted therapy in an underserved $400M+ market. The ASH exhibition, a premier hematology event, offers visibility to key stakeholders, reinforcing investor confidence in Citius Oncology’s ability to capture market share. The positive reaction aligns with the strategic milestone of product exposure at a high-profile industry conference, underscoring LYMPHIR’s potential to address unmet needs in CTCL treatment.